03 December 2021 | News
Strengthening foundation for global business
image credit- shutterstock
Japan-based pharma firm Daiichi Sankyo Company has established wholly-owned subsidiaries in Australia (Daiichi Sankyo Australia), Canada (Daiichi Sankyo Pharma Canada), and Singapore (Daiichi Sankyo Singapore).
With the establishment of these three subsidiaries, there are now 27 countries in which the Daiichi Sankyo group of companies is present.
Through these subsidiaries, Daiichi Sankyo will contribute to healthcare in countries where it has a base of operations and further strengthen the foundation for its global business, including its oncology products.